MetLife Investment Management’s RAPT Therapeutics RAPT Stock Holding History

MetLife Investment Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,969	Closed	-$141K	–	2917
2024 Q1	$141K	Hold	1,969	–	–	﹤0.01%	2372
2023 Q4	$391K	Hold	1,969	–	–	﹤0.01%	1830
2023 Q3	$262K	Hold	1,969	–	–	﹤0.01%	2041
2023 Q2	$295K	Hold	1,969	–	–	﹤0.01%	2027
2023 Q1	$289K	Buy	1,969 +243	+14%	+$49.1K	﹤0.01%	1992
2022 Q4	$273K	Hold	1,726	–	–	﹤0.01%	2047
2022 Q3	$332K	Buy	1,726 +111	+7%	+$21K	﹤0.01%	1924
2022 Q2	$236K	Buy	1,615 +236	+17%	+$31.5K	﹤0.01%	2199
2022 Q1	$243K	Buy	1,379 +509	+59%	+$96.1K	﹤0.01%	2239
2021 Q4	$256K	Hold	870	–	–	﹤0.01%	1907
2021 Q3	$216K	Hold	870	–	–	﹤0.01%	2040
2021 Q2	$221K	Buy	+870	New	+$163K	﹤0.01%	2100
2020 Q4	–	Sell	-668	Closed	-$172K	–	2305
2020 Q3	$172K	Hold	668	–	–	﹤0.01%	1949
2020 Q2	$155K	Buy	+668	New	+$103K	﹤0.01%	2043

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

MetLife Investment Management's RAPT Position: Q2 2024 in Review

MetLife Investment Management sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 1,969 shares — an estimated $141K sold.

MetLife Investment Management first reported a position in RAPT in Q2 2020 and held it in 14 quarters. The position peaked at $391K in Q4 2023. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

MetLife Investment Management reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
MetLife Investment Management sold 1,969 RAPT Therapeutics shares in Q2 2024, an estimated $141K.
MetLife Investment Management first reported a position in RAPT Therapeutics in Q2 2020 and held it in 14 quarters.
MetLife Investment Management's RAPT Therapeutics position peaked at $391K in Q4 2023.
103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.